1 | ligands for immobilization cgmp | | | | | | | 3 | 0.43% |
2 | epac agonists epac negative | | | | | | | 3 | 0.43% |
3 | camp ligands for immobilization | | | | | | | 3 | 0.43% |
4 | analogues cadpr analogues cidpr | | | | | | | 3 | 0.43% |
5 | nucleotides special task cyclic | | | | | | | 3 | 0.43% |
6 | pkg inhibitors pde resistant | | | | | | | 3 | 0.43% |
7 | inhibitors pde resistant pkg | | | | | | | 3 | 0.43% |
8 | media cyclic nucleotide affinity | | | | | | | 3 | 0.43% |
9 | chromatography media cyclic nucleotide | | | | | | | 3 | 0.43% |
10 | cgamp analogues cdiamp analogues | | | | | | | 3 | 0.43% |
11 | resistant pkg inhibitors pde | | | | | | | 3 | 0.43% |
12 | cdiamp cgamp analogues cdiamp | | | | | | | 3 | 0.43% |
13 | pde resistant pkg activators | | | | | | | 3 | 0.43% |
14 | gels diphosphate affinity gels | | | | | | | 3 | 0.43% |
15 | diphosphate affinity gels fluorescent | | | | | | | 3 | 0.43% |
16 | cyclic nucleotides fluorescent cyclic | | | | | | | 3 | 0.43% |
17 | nucleotides modulators of cng | | | | | | | 2 | 0.28% |
18 | cyclic nucleotides modulators of | | | | | | | 2 | 0.28% |
19 | task cyclic nucleotides modulators | | | | | | | 2 | 0.28% |
20 | nad analogues adpr analogues | | | | | | | 2 | 0.28% |
21 | modulators of cng ion | | | | | | | 2 | 0.28% |
22 | cng ion channels fluorescent | | | | | | | 2 | 0.28% |
23 | ion channels fluorescent cyclic | | | | | | | 2 | 0.28% |
24 | channels fluorescent cyclic nucleotides | | | | | | | 2 | 0.28% |
25 | fluorescent cyclic nucleotides peptidebased | | | | | | | 2 | 0.28% |
26 | cyclic nucleotides peptidebased pkg | | | | | | | 2 | 0.28% |
27 | nucleotides peptidebased pkg inhibitors | | | | | | | 2 | 0.28% |
28 | inhibitors metabolically activatable cnmp | | | | | | | 2 | 0.28% |
29 | metabolically activatable cnmp cnmp | | | | | | | 2 | 0.28% |
30 | activatable cnmp cnmp with | | | | | | | 2 | 0.28% |
31 | cnmp cnmp with pyrimidine | | | | | | | 2 | 0.28% |
32 | cnmp with pyrimidine nucleobase | | | | | | | 2 | 0.28% |
33 | special task cyclic nucleotides | | | | | | | 2 | 0.28% |
34 | of pkg cgmp ligands | | | | | | | 2 | 0.28% |
35 | cyclic nucleotides special task | | | | | | | 2 | 0.28% |
36 | agonists epac negative controls | | | | | | | 2 | 0.28% |
37 | camp analogues pde resistant | | | | | | | 2 | 0.28% |
38 | analogues pde resistant pka | | | | | | | 2 | 0.28% |
39 | pde resistant pka inhibitors | | | | | | | 2 | 0.28% |
40 | resistant pka inhibitors pde | | | | | | | 2 | 0.28% |